Tachyon Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

1

Active:1

Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1

1 (100.0%)

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Solid Tumor
Solid Tumor
Advanced Cancer

Interventions: Drug: TACH101

First Posted Date: 2021-10-13

Last Posted Date: 2024-08-01

Lead Sponsor: Tachyon Therapeutics, Inc.

Target Recruit Count: 30

Registration Number: NCT05076552

Locations: 🇺🇸
UCI Health, Orange, California, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
NEXT Oncology, Fairfax, Virginia, United States

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.